<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057447</url>
  </required_header>
  <id_info>
    <org_study_id>GINHL-001</org_study_id>
    <nct_id>NCT00057447</nct_id>
  </id_info>
  <brief_title>Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients</brief_title>
  <official_title>Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InterMune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InterMune</source>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b
      (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with
      progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)

      International study with sites in the Czech Republic and Poland
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    administrative reasons
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Gamma-1b</intervention_name>
    <description>100 or 200 mcg, SQ, 3x per week</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg per square meters, IV, 1x per week</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab
             therapy

          -  Patients who were on other therapy including CHOP or radiation

          -  Previous therapy must have concluded 30 days prior to enrollment

          -  Demonstrable CD20-positive tumor population in lymph nodes or bone marrow
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Williamson Bradford, MD</last_name>
    <role>Study Director</role>
    <affiliation>InterMune</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intermune Inc</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2003</study_first_submitted>
  <study_first_submitted_qc>April 2, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2003</study_first_posted>
  <last_update_submitted>October 30, 2007</last_update_submitted>
  <last_update_submitted_qc>October 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2007</last_update_posted>
  <keyword>lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

